ARTEMIS clinical trial offers triple-negative patients personalized therapy
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease, when in reality, TNBC is a catch-all diagnosis of biologically different breast cancer subtypes that lack expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2).
In patients with localized disease, a neoadjuvant chemotherapy...
Possible side effects of immunotherapy — and how to handle them
Over the past decade, immune checkpoint inhibitors have shown success in treating several types of cancer, including melanoma, non-small cell...
Biomarker predicts response to pancreatic cancer therapy
MD Anderson researchers have discovered that a protein called angiogenin (ANG) serves as a potential biomarker useful for stratifying pancreatic...
Potential biomarker linked to better outcomes in acute myeloid leukemia
Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according to a study led by Koichi Takahashi, M.D., assistant professor of Leukemia at MD Anderson. The study showed that clearance of somatic mutation at complete response, particularly in non-preleukemic genes, is associated with significantly better overall survival (OS) and cumulative incidence of relapse...
